Drug Trial Radar · NCT04685616
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,042
Planned (sponsor's estimate)
Start
Apr 14, 2022
Primary completion
Sep 2030
Study completion Sep 2032
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Takeda; University of Miami; European Organisation for Research and Treatment of Cancer - EORTC; Australasian Leukaemia and Lymphoma Group; Seagen Inc.; Canadian Cancer Trials Group
- First posted
- Dec 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry. Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation. Patients will be followed up for a minimum of 5 years after treatment.
Conditions
- Hodgkin Lymphoma
Interventions
Involved site radiotherapyRadiation
Involved site radiotherapy as per International Lymphoma Radiation Oncology Group (ILROG) guidelines. Recommended dose 30Gy
DoxorubicinDrug
See arm description
BleomycinDrug
See arm description
Brentuximab vedotinDrug
See arm description
VinblastineDrug
See arm description
DacarbazineDrug
See arm description
Haematopoietic growth factorDrug
See arm description
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: 3 years from end of treatment
Locations
72 sites in 12 countries. Site status is shown where the registry gives one.
Stanford University - (Stanford Cancer Institute)
Stanford, California · Recruiting
University of Miami School of Medicine
Miami, Florida · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Royal Adelaide Hospital
Adelaide, Australia · Recruiting
Box Hill Hospital
Box Hill, Australia · Recruiting
Royal Brisbane and Women's Hospital
Brisbane, Australia · Recruiting
Royal Darwin Hospital
Darwin, Australia · Recruiting
Liverpool Hospital
Liverpool, Australia · Recruiting
Sunshine Hospital (Western Health)
Melbourne, Australia · Recruiting
Concord Repatriation General Hospital
Sydney, Australia · Recruiting
St George Hospital
Sydney, Australia · Recruiting
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia · Recruiting
Townsville University Hospital
Townsville, Queensland, Australia · Recruiting
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium · Recruiting
Ziekenhuis Netwerk Antwerpen
Antwerp, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
CHU-UCL Namur
Namur, Belgium · Recruiting
AZ Delta Campus Rumbeke
Roeselare, West Flanders, Belgium · Recruiting
Ottowa Hospital Research Institute
Ottawa, Canada · Recruiting
Saint John Regional Hospital
Saint John, Canada · Recruiting
University Health Network Princess Margaret Cancer Centre
Toronto, Canada · Recruiting
Vancouver Cancer Centre
Vancouver, Canada · Recruiting
CancerCare Manitoba
Winnipeg, Canada · Recruiting
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada · Recruiting
Juravinski Cancer Centre
Hamilton, Ontario, Canada · Recruiting
Aarhus University Hospitak Skjeby
Aarhus, Denmark · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
St James's Hospital
Dublin, Ireland · Recruiting
St. Vincent's University Hospital
Dublin, Ireland · Recruiting
University Hospital Galway
Galway, Ireland · Recruiting
Amsterdam UMC - location VUMC
Amsterdam, Netherlands · Recruiting
Reinier de Graafweg 3-11 - Postbus 5011 - 2625 AD Delft
Delft, Netherlands · Recruiting
Universitair Medisch Centrum Groningen
Groningen, Netherlands · Recruiting
Radboud University Medical Center Nijmegen
Nijmegen, Netherlands · Recruiting
NL 331 - Haaglanden Medisch Centrum (HMC) - Haaglanden MC
The Hague, Netherlands · Recruiting
Auckland City Hospital
Auckland, New Zealand · Recruiting
Instituto Portugues de Oncologia de Lisboa Francisco Gentil
Lisbon, Portugal · Recruiting
Narodny Onkologicky Ustav
Bratislava, Slovakia · Recruiting
Hospital Del Mar
Barcelona, Spain · Recruiting
Institut Catala d'Oncologia
Barcelona, Spain · Recruiting
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.